Detail akcie OraSure Tech online

Business Summary: OraSure Technologies, Inc. is engaged in the development and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions. The Company operates through two segments: the Diagnostics segment and the Molecular Solutions segment. The Diagnostics business primarily consists of the development, manufacture, marketing, and sale of simple, easy-to-use diagnostic products and specimen collection devices using its proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Molecular Solutions business is operated by Company's subsidiaries, DNA Genotek, Diversigen, and Novosanis. The Molecular Solutions segment products primarily consist of collection kits and services used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, OraSure Technologies, Inc. revenues increased 5% to $405.5M. Net income totaled $53.7M vs. loss of $17.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects OTHER INCOME increase from $6.5M to $23.6M (income), Sales and marketing decrease of 26% to $36.3M (expense).